Tysabri PML: What the Research Record Shows

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Occupational Exposure Concerns

If you or a loved one has taken Tysabri and are concerned about PML, you need clear, evidence-based information to understand the risks and monitoring protocols. Decades of pharmacovigilance research have established a robust body of evidence on the association between natalizumab and progressive multifocal leukoencephalopathy. This page summarizes key findings from published studies to help you navigate the clinical record.

Medical Evidence: Tysabri and PML Risk

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe and often fatal brain infection caused by the JC virus. Progressive multifocal leukoencephalopathy is an opportunistic viral infection of the brain caused by the JC virus (JCV), which typically only occurs in patients who are immunocompromised and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on MRI findings, detection of JCV DNA in cerebrospinal fluid, and brain biopsy in ambiguous cases. Early recognition is critical because PML can rapidly worsen. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking lymphocyte migration into the central nervous system. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JCV, allowing reactivation of latent virus. The FDA-approved labeling includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism and Clinical Presentation of PML

The mechanistic pathway linking Tysabri to PML involves reduced immune surveillance in the brain. By inhibiting lymphocyte trafficking, Tysabri decreases the ability of the immune system to control JCV replication. This allows the virus to infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients with anti-JCV antibodies, as these individuals harbor latent virus that can reactivate. Duration of therapy amplifies this risk, with cases reported after as few as eight doses in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In the clinical trial program, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). FDA adverse-event reports frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they highlight the range of neurological symptoms that may overlap with early PML signs. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Implications for Illinois Patients

Risk anchors for affected patients include the adequacy of warnings regarding Tysabri and PML. The boxed warning clearly states that Tysabri increases PML risk and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, patients may not fully understand the magnitude of risk or the need for vigilant monitoring. Attorney-related considerations arise when patients develop PML after Tysabri therapy, particularly if they were not adequately informed of the risk or if monitoring was insufficient. The timeline between exposure and documented harm can vary; PML has occurred after as few as eight doses and after longer treatment durations beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Legal claims may focus on whether healthcare providers adhered to the TOUCH program requirements and whether patients received appropriate risk-benefit counseling. In summary, Tysabri is associated with a well-documented risk of PML, driven by anti-JCV antibody status, treatment duration, and prior immunosuppressant use. The clinical presentation of PML is severe, often leading to death or disability. Patients who develop PML after Tysabri exposure may have legal recourse if warnings were inadequate or monitoring was substandard. The evidence underscores the importance of strict adherence to risk mitigation strategies and informed consent.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it increase the risk of PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML) by blocking lymphocyte migration into the brain, reducing immune surveillance against JC virus. This allows the virus to reactivate and infect oligodendrocytes, causing severe brain damage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options do Illinois patients have if they developed PML after Tysabri exposure?

Patients may have legal claims if they were not adequately warned of the PML risk or if monitoring was insufficient. Legal recourse can involve proving inadequate informed consent or failure to adhere to the TOUCH Prescribing Program requirements. Consulting an attorney experienced in Tysabri PML cases is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.